Fluphenazine

Generic Name: Fluphenazine

Brand Names: Modecate

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆F_₃N_₃OS

CAS Number: 69-23-8

Unique Ingredient Identifier: S79426A41Z

Background: A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.

Indication: For management of manifestations of psychotic disorders.

Associated Conditions: Chorea, Depression, Gilles de la Tourette's Syndrome, Psychosis

Associated Therapies: Sedation

Clinical Trials

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

First Posted Date: 2015-11-09

Last Posted Date: 2019-01-23

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 296

Registration Number: NCT02600741

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

First Posted Date: 2014-12-04

Last Posted Date: 2018-10-11

Lead Sponsor: Technical University of Munich

Target Recruit Count: 21

Registration Number: NCT02307396

Locations: 🇩🇪
Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany

D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement

Phase 2

Completed

Conditions: Pathological Gambling

Interventions: Drug: Haloperidol
Drug: Fluphenazine
Drug: Dexedrine
Drug: Placebo
Behavioral: Slot Machine

First Posted Date: 2014-07-30

Last Posted Date: 2016-04-25

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 60

Registration Number: NCT02203786

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Fluphenazine Hydrochloride for Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Placebo
Drug: Fluphenazine

First Posted Date: 2009-06-29

Last Posted Date: 2017-03-31

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 15

Registration Number: NCT00929578

Locations: 🇺🇸
Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States
🇺🇸
Robert Wood Johnson Medical School, Psoriasis Center of Excellence, New Brunswick, New Jersey, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy